Ascentage Pharma Group International (NASDAQ:AAPG) Shares Down 7% – What’s Next?

Posted by Brian Himes on May 28th, 2026

Shares of Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG – Get Free Report) dropped 7% during mid-day trading on Thursday . The stock traded as low as $19.08 and last traded at $19.4350. Approximately 4,313 shares were traded during trading, an increase of 9% from the average daily volume of 3,955 shares. The stock had previously closed at $20.90.

Wall Street Analyst Weigh In

AAPG has been the subject of several research reports. BTIG Research reissued a “buy” rating and set a $48.00 price objective on shares of Ascentage Pharma Group International in a research report on Monday, April 13th. Deutsche Bank Aktiengesellschaft assumed coverage on shares of Ascentage Pharma Group International in a research report on Friday, April 24th. They set a “buy” rating and a $40.00 price objective for the company. Finally, China Intl Cap upgraded shares of Ascentage Pharma Group International to a “strong-buy” rating in a report on Monday, April 6th. Two research analysts have rated the stock with a Strong Buy rating and six have assigned a Buy rating to the stock. According to MarketBeat, the stock has a consensus rating of “Buy” and a consensus price target of $46.67.

Get Our Latest Analysis on Ascentage Pharma Group International

Ascentage Pharma Group International Stock Down 2.4%

The company’s fifty day moving average is $23.23 and its 200 day moving average is $25.90. The company has a current ratio of 1.79, a quick ratio of 1.77 and a debt-to-equity ratio of 0.57.

Ascentage Pharma Group International (NASDAQ:AAPG – Get Free Report) last announced its earnings results on Wednesday, March 25th. The company reported ($0.52) EPS for the quarter. The company had revenue of $24.72 million for the quarter. As a group, equities research analysts predict that Ascentage Pharma Group International – Unsponsored ADR will post -1.09 EPS for the current year.

Institutional Trading of Ascentage Pharma Group International

A number of large investors have recently added to or reduced their stakes in AAPG. XY Capital Ltd lifted its stake in Ascentage Pharma Group International by 224.2% in the third quarter. XY Capital Ltd now owns 18,120 shares of the company’s stock valued at $707,000 after acquiring an additional 12,530 shares during the last quarter. UBS Group AG lifted its stake in Ascentage Pharma Group International by 149.4% in the third quarter. UBS Group AG now owns 18,345 shares of the company’s stock valued at $716,000 after acquiring an additional 10,988 shares during the last quarter. Hsbc Holdings PLC acquired a new stake in Ascentage Pharma Group International in the second quarter valued at $391,000. Citadel Advisors LLC acquired a new stake in Ascentage Pharma Group International in the third quarter valued at $383,000. Finally, ABC Arbitrage SA acquired a new stake in Ascentage Pharma Group International in the third quarter valued at $204,000.

Ascentage Pharma Group International Company Profile

(Get Free Report)

Ascentage Pharma Group International is a clinical‐stage biopharmaceutical company focused on developing small‐molecule therapeutics that modulate programmed cell death pathways, including the Bcl‐2 family and the MDM2–p53 axis. Its pipeline features orally bioavailable inhibitors such as APG-2575, a selective Bcl-2 inhibitor, and APG-115, a potent MDM2 antagonist, both aimed at reactivating apoptosis in cancer cells across hematologic malignancies and solid tumors.

Founded in 2008 by biotechnology entrepreneur Dr.